| L9LS MAb in Malian Infants (NCT06461026) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-08-19 |
| Pregnancy Registry in Mali (NCT06468319) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-08-05 |
| Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age (NCT06546423) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-07-12 |
| Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only (NCT06721585) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-07-10 |
| Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study (NCT06339177) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-07-02 |
| Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults (NCT06441968) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-07-01 |
| Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults (NCT06444048) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-06-26 |
| pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) (NCT06253507) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-06-25 |
| Advancing Transplantation Outcomes in Children (NCT06055608) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-05-22 |
| CAR-T Cell Therapy for Desensitization in Kidney Transplantation (NCT06056102) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-05-09 |
| Protocol CAUSE-03 / CHEETAH (NCT06136091) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-05-08 |
| Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function (NCT03896750) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-04-17 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease (NCT06325709) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-04-17 |
| Safety Study of SLV213 for the Treatment of COVID-19. (NCT06146374) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-04-09 |
| Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 (NCT06071767) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-04-01 |
| Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV. (NCT06332339) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-03-15 |
| Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates (NCT06075745) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-03-05 |
| Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis (NCT05630872) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-02-13 |
| Tocilizumab in Lung Transplantation (NCT06033196) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-02-13 |
| Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (NCT05660980) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-24 |
| A Study of Doxycycline to Treat Chlamydial Infection (NCT05840159) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-19 |
| Investigation of Immune Amnesia Following Measles Infection in Select African Regions (NCT06153979) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-16 |
| Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity (NCT06169150) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-12 |
| Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy (NCT06005610) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-04 |
| The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies (NCT06006546) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-03 |
| Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI (NCT05079451) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-01 |
| Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy (NCT04046107) | National Institute of Allergy and Infectious Diseases (NIAID) | 2024-01-01 |
| Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (NCT05917522) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-12-07 |
| Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis (NCT05383742) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-12-07 |
| Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency (NCT03733067) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-11-30 |
| Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria (NCT05750459) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-11-29 |
| A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV (NCT06033209) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-11-27 |
| Evaluation and Follow-up of People With Tick-borne Diseases (NCT04318925) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-11-13 |
| Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers (NCT06120244) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-11-01 |
| Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies (NCT04772170) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-10-23 |
| Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model (NCT05436444) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-10-23 |
| A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (NCT05945485) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-10-16 |
| Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (NCT05586230) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-10-03 |
| Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons (NCT05683834) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-09-22 |
| To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV (NCT05854381) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-09-19 |
| Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults (NCT06026514) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-09-18 |
| Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations (NCT03278912) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-09-08 |
| Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults (NCT05930197) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-08-31 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV (NCT05903339) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-08-29 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults (NCT05968989) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-08-09 |
| Neonatal Phase 1 Valacyclovir Study (NCT05468619) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-08-07 |
| Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults (NCT05913973) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-08-04 |
| A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy (NCT05612178) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-07-26 |
| CD40L Antagonism in Rheumatoid Arthritis (RA) (NCT05306353) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-07-25 |
| Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA (NCT05710640) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-06-27 |
| Safety of Intravenous Apramycin in Adults (NCT05590728) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-06-16 |
| A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV (NCT05630885) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-05-30 |
| Daratumumab in Primary Antiphospholipid Syndrome (NCT05671757) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-05-26 |
| L9LS MAb in Malian Adults (NCT05816330) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-05-25 |
| Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders (NCT05656365) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-05-23 |
| Siplizumab in T1DM (NCT05574335) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-05-18 |
| Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV (NCT05551273) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-05-05 |
| Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products (NCT02242968) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-04-24 |
| Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) (NCT05645757) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-04-19 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV (NCT05781542) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-04-10 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV (NCT05828095) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-04-05 |
| A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (NCT05755620) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-04-05 |
| Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC (NCT05734508) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-03-23 |
| A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox (NCT05740982) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-03-22 |
| Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (NCT05580458) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-03-13 |
| A Repository to Study Host-Microbiome Interactions in Health and Disease (NCT05656378) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-03-09 |
| COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study (NCT05518487) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-02-20 |
| Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis (NCT05285891) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-02-07 |
| A Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB0115-00-AB (VRC01.23LS), Administered Intravenously or Subcutaneously to Healthy Adults (NCT05627258) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-01-30 |
| Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants. (NCT04915768) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-01-23 |
| Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata (NCT05398809) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-01-18 |
| Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD) (NCT05600907) | National Institute of Allergy and Infectious Diseases (NIAID) | 2023-01-02 |
| The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel Disease (NCT05652491) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-12-09 |
| Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus (NCT05306873) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-11-30 |
| Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV (NCT04334915) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-11-22 |
| Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (NCT05436535) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-11-21 |
| Phase 2 Shigella Vaccine and Challenge (NCT04242264) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-10-12 |
| Tecovirimat for Treatment of Monkeypox Virus (NCT05559099) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-10-10 |
| A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 (NCT05406583) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-10-05 |
| A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa (NCT05453578) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-10-03 |
| Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus (NCT05048238) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-09-30 |
| Linezolid Dosing Strategies in Drug-Resistant TB (NCT05007821) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-09-27 |
| Anti-malaria MAb in Kenyan Children (NCT05400655) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-09-14 |
| Safety and Immunogenicity of CJCV2 With and Without ALFQ (NCT05500417) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-09-13 |
| Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine (NCT05512949) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-09-09 |
| Study of Tecovirimat for Human Mpox Virus (NCT05534984) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-09-08 |
| Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III (NCT05494801) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-08-25 |
| Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV (NCT05471076) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-08-22 |
| A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults (NCT05470400) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-08-15 |
| Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (NCT05104723) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-08-12 |
| Respiratory Virus Sampling and Repository (NCT05266222) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-08-11 |
| Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis (NCT05333471) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-08-08 |
| NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) (NCT05189925) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-07-22 |
| Targeted Investigation of Microbiome Elimination (NCT05177328) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-07-18 |
| Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults (NCT05398796) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-07-11 |
| Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists (NCT05463133) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-07-08 |
| Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine (NCT05027932) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-06-27 |
| Anthrax AV7909 Liquid vs Lyophilized (NCT04660201) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-05-25 |
| Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults (NCT05292391) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-05-23 |
| VIBRANT: VIB4920 for Active Lupus Nephritis (NCT05201469) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-05-16 |